

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1672)

VOLUNTARY ANNOUNCEMENT

**GANOVO[®] IS ELIGIBLE FOR THE BASIC MEDICAL
INSURANCE OF ZHEJIANG PROVINCE — REIMBURSEMENT
-BY-DISEASE**

The board of directors of Ascletis Pharma Inc. (the “**Company**”) is pleased to announce that Ganovo[®] (Danoprevir) is eligible for the Basic Medical Insurance of Zhejiang Province — Reimbursement-by-disease for outpatients with Hepatitis C.

By Order of the Board of Directors

Ascletis Pharma Inc.

歌禮製藥有限公司

Jinzi Jason WU

Chairman

Hangzhou, the People’s Republic of China

April 15, 2019

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.